Inhibitor eradication with rituximab in haemophilia: Where do we stand?

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalArticlepeer-review


Rituximab is a humanized chimeric anti-CD20 monoclonal antibody initially developed for the treatment of some haematological malignancies. Thanks to its ability to rapidly and specifically deplete B cells, it has also been used in a variety of autoimmune disorders, haematological or not. In this context, during the last decade several small case series have documented successful inhibitor eradication with rituximab, alone or in combination with other immunosuppressive agents, in patients with acquired haemophilia A refractory to standard therapy. In addition, a number of investigators have recently used this agent in patients with congenital haemophilia A or B and alloantibodies refractory to first-line treatment. This article critically reviews the current knowledge on the use of rituximab in acquired haemophilia or congenital haemophilia complicated by alloantibodies, also providing treatment algorithms for the management of these conditions.

Original languageEnglish
Pages (from-to)600-608
Number of pages9
JournalBritish Journal of Haematology
Issue number5
Publication statusPublished - 2014


  • Acquired haemophilia
  • Alloantibodies
  • Autoantibodies
  • Congenital haemophilia
  • Inhibitors
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)


Dive into the research topics of 'Inhibitor eradication with rituximab in haemophilia: Where do we stand?'. Together they form a unique fingerprint.

Cite this